The European Partnership for Personalised Medicine, EP PerMed (supported by the European Union under Horizon Europe, Grant Agreement N° 101137129), is a platform for joint programming of national and European regional research and innovation supporting activities putting into action The Strategic Research & Innovation Agenda (SRIA) for Personalised Medicine (2023), SRIA for PM (2023), through dedicated research, development and innovation funding.

EP PerMed funding organisations, listed below, have agreed to launch the joint transnational call 2024 (JTC2024), co-funded by the EU, to fund multinational innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe in this field. The JTC2024 will be conducted simultaneously by the participating funding organisations in their respective region/country and coordinated centrally by the Joint Call Secretariat (JCS), hosted by the French National Research Agency, (ANR), France.

The call will be implemented in two stages, i.e. a pre- and a full-proposal phase. The call calendar, including the deadline for pre- and full-proposal submission, will be available soon. The call is expected to be launched beginning of January 2024.

The available budget for this call is 40 Mio. € (approx.).

An open information day introducing the JTC2024 to the research community will be organised. More information (including the date and registration) will follow soon.

The JTC2024 will aim to fund research that fosters the identification or validation of targets for personalised medicine approaches. Applicants submitting a proposal to this call must combine the research on new and advanced targets with companion biomarker research (companion diagnostics). Consortia are required to be transnational, interdisciplinary and trans-sectoral as well as to clearly outline the personalised medicine perspective in the research proposed.

The overall objectives of the JTC2024 are to

• Support research projects aiming at identifying or validating targets for personalised medicine approaches in combination with development of companion biomarkers or other markers to allow for monitoring of treatment outcomes and patient stratification;
• Encourage and enable interdisciplinary collaborations by combining pre-clinical and clinical research in translational projects, and multi-actor research by engaging a range of other relevant disciplines such as bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to empower the implementation of PM; and
• Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations.

Joint research proposals may be submitted by applicants belonging to the following categories (subject to regional/national funding regulations):

• Academia (research teams working in universities, other higher education institutions) or research institutes;
• Clinical/public health sector (research teams working in hospitals/public health and/or other healthcare settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses) in the research teams is encouraged;
• Private for-profit (industry) partners, e.g. SME (small and medium-sized enterprises) and private non-profit partners, e.g. foundations, associations or non-governmental organisations.

More information about the eligibility criteria and rules regarding consortium composition will be available soon.

In case of interest, please click on "m'interessa" and we will contact you.